Alpha galactosylceramide liposomal - REGiMMUNE

Drug Profile

Alpha galactosylceramide liposomal - REGiMMUNE

Alternative Names: KRN-7000 liposomal; liposomal KRN-7000; liposomal RGI-7000; RGI 3100; RGI-2001; RGI7000 liposomal; ToleroVax

Latest Information Update: 27 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator REGiMMUNE
  • Developer JDRF; Pfizer; REGiMMUNE
  • Class Adjuvants; Antineoplastics; Galactosylceramides; Small molecules
  • Mechanism of Action Blood coagulation factor replacements; Enzyme replacements; Galactosylceramidase replacements; Immunosuppressants; Natural killer cell stimulants; Regulatory T-lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Graft-versus-host disease
  • Preclinical Haemophilia; Lysosomal-storage diseases; Type 1 diabetes mellitus

Most Recent Events

  • 09 Mar 2017 Immunogenicity data from a phase I/IIa trial in Graft-versus-Host Disease released by REGiMMUNE
  • 21 Oct 2016 RGI 3100 is still in preclinical development for Type-1 diabetes in Japan (REGiMMUNE pipeline, October 2016)
  • 19 Oct 2016 Preclinical trials in Haemophilia in Japan before October 2016 (REGiMMUNE pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top